Kilitch Drugs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE729D01010
NSEID: KILITCH
BSEID: 524500

INR

336.20

-7.05 (-2.05%)

BSENSE

Dec 05

BSE+NSE Vol: 110

{
  "main_header": {
    "sid": 189669,
    "name": "Kilitch Drugs",
    "stock_name": "Kilitch Drugs",
    "full_name": "Kilitch Drugs (India) Ltd",
    "name_url": "stocks-analysis/kilitch-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "336.20",
    "chg": -7.05,
    "chgp": "-2.05%",
    "dir": -1,
    "prev_price": "343.25",
    "mcapval": "587.70 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524500,
    "symbol": "KILITCH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE729D01010",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "110 ",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kilitch-drugs-189669-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Kilitch Drugs technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-kilitch-drugs-technically-bullish-or-bearish-3747608",
        "imagepath": "",
        "date": "2025-12-05 08:23:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Kilitch Drugs’ Current Market Position</strong></p>\n<p>Kilitch Drugs is trading at ₹343.25, marginally above its previous close of ₹341.80. The stock’s 52-week range spans from ₹271.30 to ₹500.05, indicating significant volatility over the past year. Today’s intraday movement saw a high of ₹360.00 and a low of ₹337.95, reflecting some short-term price fluctuations.</p>\n<p>While the stock price remains comfortably above its yearly low, it is still well below the 52-week high, suggesting that the stock has not regained its peak momentum. This price behaviour is an important backdrop when analysing the technical indicators.</p>\n<p><strong>Technical Trend and Moving Averages</strong></p>\n<p>The overall technical trend for Kilitch Drugs recently shifted from bearish to mildly bearish ..."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-technical-momentum-shifts-amid-mixed-market-signals-3747477",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugsInd_technicaldot_3747477.png",
        "date": "2025-12-05 08:01:12",
        "description": "Kilitch Drugs (India) has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish indicators across multiple timeframes. Recent market data reveals a subtle transition in price dynamics, with key technical parameters signalling a cautious outlook for the pharmaceutical company amid broader sector trends."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-shares-shift-to-bearish-momentum-amid-technical-downgrade-3745177",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugsInd_technicaldot_3745177.png",
        "date": "2025-12-04 08:01:15",
        "description": "Kilitch Drugs (India) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. As the stock navigates a challenging phase within the Pharmaceuticals & Biotechnology sector, recent evaluation adjustments highlight evolving market dynamics and investor sentiment."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-technical-momentum-shifts-amid-mixed-market-signals-3742734",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugsInd_technicaldot_3742734.png",
        "date": "2025-12-03 08:01:41",
        "description": "Kilitch Drugs (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of market forces and analytical perspectives. Recent evaluation adjustments highlight a transition in price trends and technical indicators, offering investors a detailed view of the stock’s current positioning within a volatile market environment."
      },
      {
        "title": "Kilitch Drugs Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kilitch-drugs-downgraded-to-sell-by-marketsmojo-amid-weak-financial-and-technical-signals-3738120",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugs_mojoScore_3738120.png",
        "date": "2025-12-01 10:09:02",
        "description": "Kilitch Drugs has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by recent financial and technical developments. The pharmaceutical company’s assessment now reflects a more cautious outlook, influenced by a combination of flat financial trends, valuation considerations, and technical indicators."
      },
      {
        "title": "Is Kilitch Drugs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-kilitch-drugs-overvalued-or-undervalued-3730110",
        "imagepath": "",
        "date": "2025-11-26 08:14:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics and Financial Health</strong></p>\n<p>Kilitch Drugs trades at a price-to-earnings (PE) ratio of approximately 22.3, which is moderate within the pharmaceutical industry context. Its price-to-book value stands at 2.32, indicating that the stock is priced at more than twice its book value, a common scenario for companies with growth potential in this sector. The enterprise value to EBITDA ratio of 19.36 suggests that the market values the company at nearly 19.4 times its earnings before interest, taxes, depreciation, and amortisation, a figure that is neither excessively high nor particularly low.</p>\n<p>Importantly, the company’s PEG ratio is notably low at 0.41, signalling that the stock’s price is relatively inexpensive compared to its earnings growth rate. This is a positi..."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-faces-bearish-momentum-amid-technical-downgrade-3727313",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KilitchDrugsInd_technicaldot_3727313.png",
        "date": "2025-11-25 08:01:27",
        "description": "Kilitch Drugs (India) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The pharmaceutical company’s stock price movements and technical parameters suggest evolving market sentiment amid broader sector dynamics."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-technical-momentum-shifts-amid-mixed-indicator-signals-3723621",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/KilitchDrugsInd_technicaldot_3723621.png",
        "date": "2025-11-24 08:00:45",
        "description": "Kilitch Drugs (India) has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of indicator signals across multiple timeframes. Recent market data reveals a transition from a predominantly bearish stance to a mildly bearish outlook, underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages."
      },
      {
        "title": "Is Kilitch Drugs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-kilitch-drugs-overvalued-or-undervalued-3709732",
        "imagepath": "",
        "date": "2025-11-18 08:20:09",
        "description": "As of 17 November 2025, the valuation grade for Kilitch Drugs has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 22.78, an EV to EBITDA of 19.76, and a PEG ratio of 0.42. These ratios suggest that Kilitch Drugs is positioned competitively within its industry.\n\nIn comparison to its peers, Kilitch Drugs holds a PE ratio that is significantly lower than Sun Pharma's 36.69 and Divi's Lab's 69.78, both of which are categorized as expensive. Meanwhile, it is on par with Aurobindo Pharma, which has a PE of 21.23, and slightly below Cipla's 22.81, both of which are rated as fair or attractive. Notably, Kilitch Drugs has outperformed the Sensex over the longer term, with a 3-year return of 117.32% compared to the Sensex's 37.57%. This performance, coupled with its fair valuation, su..."
      }
    ],
    "total": 266,
    "sid": "189669",
    "stock_news_url": "https://www.marketsmojo.com/news/kilitch-drugs-india-189669"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Nov-2025",
      "details": "We are hereby submitting the copy publication of extract of financial results for the quarter ended 30th September 2025",
      "source": "BSE"
    },
    {
      "caption": "Monitoring Agency Report",
      "datetime": "14-Nov-2025",
      "details": "We are submitting herewith the report received from monitoring agency for the quarter ended 30th September 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "14-Nov-2025",
      "details": "We are submitting herewith the Press Release of Financial Results for H126",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Kilitch Drugs (India) Ltd has declared <strong>5%</strong> dividend, ex-date: 20 Sep 19",
          "dt": "2019-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Kilitch Drugs (India) Ltd has announced <strong>2:23</strong> rights issue, ex-date: 15 Jul 25",
          "dt": "2025-07-15",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Is Kilitch Drugs technically bullish or bearish?

2025-12-05 08:23:26

Overview of Kilitch Drugs’ Current Market Position

Kilitch Drugs is trading at ₹343.25, marginally above its previous close of ₹341.80. The stock’s 52-week range spans from ₹271.30 to ₹500.05, indicating significant volatility over the past year. Today’s intraday movement saw a high of ₹360.00 and a low of ₹337.95, reflecting some short-term price fluctuations.

While the stock price remains comfortably above its yearly low, it is still well below the 52-week high, suggesting that the stock has not regained its peak momentum. This price behaviour is an important backdrop when analysing the technical indicators.

Technical Trend and Moving Averages

The overall technical trend for Kilitch Drugs recently shifted from bearish to mildly bearish ...

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals

2025-12-05 08:01:12

Kilitch Drugs (India) has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish indicators across multiple timeframes. Recent market data reveals a subtle transition in price dynamics, with key technical parameters signalling a cautious outlook for the pharmaceutical company amid broader sector trends.

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals

2025-12-04 08:01:15

Kilitch Drugs (India) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. As the stock navigates a challenging phase within the Pharmaceuticals & Biotechnology sector, recent evaluation adjustments highlight evolving market dynamics and investor sentiment.

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals

2025-12-03 08:01:41

Kilitch Drugs (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of market forces and analytical perspectives. Recent evaluation adjustments highlight a transition in price trends and technical indicators, offering investors a detailed view of the stock’s current positioning within a volatile market environment.

Kilitch Drugs Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-12-01 10:09:02

Kilitch Drugs has experienced a revision in its market evaluation, reflecting a shift in analytical perspective driven by recent financial and technical developments. The pharmaceutical company’s assessment now reflects a more cautious outlook, influenced by a combination of flat financial trends, valuation considerations, and technical indicators.

Is Kilitch Drugs overvalued or undervalued?

2025-11-26 08:14:05

Valuation Metrics and Financial Health

Kilitch Drugs trades at a price-to-earnings (PE) ratio of approximately 22.3, which is moderate within the pharmaceutical industry context. Its price-to-book value stands at 2.32, indicating that the stock is priced at more than twice its book value, a common scenario for companies with growth potential in this sector. The enterprise value to EBITDA ratio of 19.36 suggests that the market values the company at nearly 19.4 times its earnings before interest, taxes, depreciation, and amortisation, a figure that is neither excessively high nor particularly low.

Importantly, the company’s PEG ratio is notably low at 0.41, signalling that the stock’s price is relatively inexpensive compared to its earnings growth rate. This is a positi...

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals

2025-11-25 08:01:27

Kilitch Drugs (India) has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. The pharmaceutical company’s stock price movements and technical parameters suggest evolving market sentiment amid broader sector dynamics.

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Indicator Signals

2025-11-24 08:00:45

Kilitch Drugs (India) has exhibited a nuanced shift in its technical momentum, reflecting a complex interplay of indicator signals across multiple timeframes. Recent market data reveals a transition from a predominantly bearish stance to a mildly bearish outlook, underscored by mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages.

Is Kilitch Drugs overvalued or undervalued?

2025-11-18 08:20:09

As of 17 November 2025, the valuation grade for Kilitch Drugs has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 22.78, an EV to EBITDA of 19.76, and a PEG ratio of 0.42. These ratios suggest that Kilitch Drugs is positioned competitively within its industry. In comparison to its peers, Kilitch Drugs holds a PE ratio that is significantly lower than Sun Pharma's 36.69 and Divi's Lab's 69.78, both of which are categorized as expensive. Meanwhile, it is on par with Aurobindo Pharma, which has a PE of 21.23, and slightly below Cipla's 22.81, both of which are rated as fair or attractive. Notably, Kilitch Drugs has outperformed the Sensex over the longer term, with a 3-year return of 117.32% compared to the Sensex's 37.57%. This performance, coupled with its fair valuation, su...

View All News